The provider assesses the presence of estrogen or progesterone receptors, cell proteins that bind to specific molecules, within tumor cells in female patients, 18 years of age or older. A tumor that is estrogen or progesterone receptor positive (ER+ or PR+) responds to medications that interfere with the production or utilization of estrogen.
For clinical responsibility, terminology, tips and additional info
start codify free trial.